{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:08:58Z","timestamp":1788754138809,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"},{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jval.2020.09.004","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T11:09:38Z","timestamp":1603883378000},"page":"91-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease"],"prefix":"10.1016","volume":"24","author":[{"given":"Ekkehard","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Klint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Neine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Meszaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.jval.2020.09.004_bib3","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jval.2020.09.004_bib4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1586\/14760584.2015.1004317","article-title":"Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives","volume":"14","author":"Whelan","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"10.1016\/j.jval.2020.09.004_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177082","article-title":"Short-term changes in the health state of children with group B meningococcal disease: a prospective, national cohort study","volume":"12","author":"Kennedy","year":"2017","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.jval.2020.09.004_bib6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.jval.2020.09.004_bib7","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","article-title":"The disease burden of invasive meningococcal serogroup B disease in Canada","volume":"32","author":"Bettinger","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.jval.2020.09.004_bib8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/INF.0000000000000043","article-title":"The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children","volume":"33","author":"Wang","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.jval.2020.09.004_bib9","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/hec.3259","article-title":"Measuring health spillovers for economic evaluation: a case study in meningitis","volume":"25","author":"Al-Janabi","year":"2016","journal-title":"Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2020.09.004_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40272-012-0006-0","article-title":"Counting the cost of meningococcal disease : scenarios of severe meningitis and septicemia","volume":"15","author":"Wright","year":"2013","journal-title":"Paediatric Drugs"},{"issue":"39","key":"10.1016\/j.jval.2020.09.004_bib11","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1016\/j.vaccine.2014.07.019","article-title":"Costs of surviving meningococcal disease in Spain: Evaluation for two cases of severe meningitis and septicaemia","volume":"32","author":"Darb\u00e0","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jval.2020.09.004_bib12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jiph.2015.10.016","article-title":"Lifetime cost of meningococcal disease in France: scenarios of severe meningitis and septicemia with purpura fulminans","volume":"9","author":"Benard","year":"2016","journal-title":"J\u00a0Infect Public Health"},{"issue":"12","key":"10.1016\/j.jval.2020.09.004_bib13","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.vaccine.2019.01.013","article-title":"The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany","volume":"37","author":"Scholz","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2020.09.004_bib15","unstructured":"Rodrigues F. Portuguese Meningococcus Group B Vaccine Effectiveness Study (PT-BEST): preliminary results. Paper presented at: 15th European Meningococcal and Haemophilus Disease Society (EMGM) Congress 2019; Lisbon, Portugal."},{"key":"10.1016\/j.jval.2020.09.004_bib26","author":"El Pais"},{"issue":"4","key":"10.1016\/j.jval.2020.09.004_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of infants with Meningococcal Group B Vaccine (4CMenB) in England","volume":"382","author":"Ladhani","year":"2020","journal-title":"New England J Med"},{"key":"10.1016\/j.jval.2020.09.004_bib29","unstructured":"Institut National de Sante Publique du Quebec (INSPQ). Assessment report: epidemiological impact of the vaccination campaign against serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region in 2014: report of 30 June 2018. Quebec\u00a02018."},{"key":"10.1016\/j.jval.2020.09.004_bib30","unstructured":"Ladhani S. Increase in group W meningococcal disease in the UK. Paper presented at: 15th European Meningococcal and Haemophilus Disease Society (EMGM) Congress. 2019; Lisbon, Portugal."},{"key":"10.1016\/j.jval.2020.09.004_bib33","series-title":"Vaccination against meningococcal disease","year":"2018"},{"issue":"23","key":"10.1016\/j.jval.2020.09.004_bib34","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical\u00a0modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jval.2020.09.004_bib35","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4161\/hv.23888","article-title":"Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence","volume":"9","author":"Pouwels","year":"2013","journal-title":"Human Vaccines Immunother"},{"key":"10.1016\/j.jval.2020.09.004_bib36","first-page":"g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"BMJ (Clinical Research Ed)"},{"key":"10.1016\/j.jval.2020.09.004_bib37","series-title":"A\u00a0quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study","author":"Hanquet","year":"2014"},{"issue":"42","key":"10.1016\/j.jval.2020.09.004_bib38","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.vaccine.2014.07.096","article-title":"Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada","volume":"32","author":"Tu","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jval.2020.09.004_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123383","article-title":"Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme","volume":"10","author":"Tirani","year":"2015","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.jval.2020.09.004_bib40","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1080\/21645515.2016.1160177","article-title":"Vaccinating Italian infants with a\u00a0new multicomponent vaccine (Bexsero(R)) against meningococcal B disease: A cost-effectiveness analysis","volume":"12","author":"Gasparini","year":"2016","journal-title":"Human Vaccines Immunother"},{"issue":"29","key":"10.1016\/j.jval.2020.09.004_bib41","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.vaccine.2016.04.004","article-title":"Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero((R)) to reduce meningococcal group B disease in Germany","volume":"34","author":"Christensen","year":"2016","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.jval.2020.09.004_bib42","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.vaccine.2016.03.020","article-title":"Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France","volume":"34","author":"Lecocq","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jval.2020.09.004_bib43","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00038-016-0821-0","article-title":"Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel","volume":"61","author":"Ginsberg","year":"2016","journal-title":"Inter J Public Health"},{"issue":"1-2","key":"10.1016\/j.jval.2020.09.004_bib53","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0264-410X(01)00254-7","article-title":"Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program","volume":"20","author":"Bos","year":"2001","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jval.2020.09.004_bib54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00019053-200624020-00004","article-title":"Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in The Netherlands","volume":"24","author":"Bos","year":"2006","journal-title":"PharmacoEconomics"},{"issue":"2","key":"10.1016\/j.jval.2020.09.004_bib57","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.vaccine.2016.11.076","article-title":"Modelling the cost-effectiveness of catch-up MenB (Bexsero) vaccination in England","volume":"35","author":"Christensen","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2020.09.004_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2020.08.007","article-title":"Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England","author":"Beck","year":"2020","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.jval.2020.09.004_bib45","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1017\/S095026881300294X","article-title":"Modelled evaluation of multi-component meningococcal vaccine (Bexsero(R)) for the prevention of invasive meningococcal disease in infants and adolescents in the UK","volume":"142","author":"Huels","year":"2014","journal-title":"Epidemiol Infection"},{"issue":"12","key":"10.1016\/j.jval.2020.09.004_bib48","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jval.2020.09.004_bib49","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1371\/journal.pmed.0050074","article-title":"Social contacts and mixing patterns relevant to the spread of infectious diseases","volume":"5","author":"Mossong","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.jval.2020.09.004_bib50","unstructured":"Pizza M, Biolchi A, De Angelis G, et\u00a0al. Abstract ESPID19-0255: a multicomponent meningococcal serogroup b vaccine developed for serogroup b meningococci elicits cross-reactive immunity against serogroups C, W and Y_AKR. Paper presented at: European Society for Paediatric Infectious Diseases, 37th Annual Meeting\u00a02019."},{"issue":"4","key":"10.1016\/j.jval.2020.09.004_bib51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B vaccine and meningococcal carriage in adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jval.2020.09.004_bib84","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1016\/j.vaccine.2012.03.011","article-title":"Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines","volume":"30","author":"Ladhani","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jval.2020.09.004_bib85","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1017\/S0950268802007549","article-title":"National enhanced surveillance of meningococcal disease in England, Wales and Northern\u00a0Ireland, January 1999-June 2001","volume":"129","author":"Shigematsu","year":"2002","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jval.2020.09.004_bib86","series-title":"UK PHE progress report v6: Progress report on 4CMenB (Bexsero) vaccine coverage and effectiveness in England. 3rd annual report 1 September 2015-31 August 2018","author":"Parikh","year":"2018"},{"issue":"7","key":"10.1016\/j.jval.2020.09.004_bib59","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00019053-200826070-00008","article-title":"Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK","volume":"26","author":"Gani","year":"2008","journal-title":"PharmacoEconomics"},{"issue":"3","key":"10.1016\/j.jval.2020.09.004_bib58","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1741-3729.2010.00601.x","article-title":"Long-term effects of child death on parents' health related quality of life: a dyadic analysis","volume":"59","author":"Song","year":"2010","journal-title":"Fam Relat"},{"issue":"2-3","key":"10.1016\/j.jval.2020.09.004_bib87","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.healthpol.2014.02.009","article-title":"Concerns for severity in priority setting in health care: a review of trade-off data in preference studies and implications for societal willingness to pay for a QALY","volume":"116","author":"Nord","year":"2014","journal-title":"Health Policy (Amsterdam, Netherlands)"},{"issue":"26","key":"10.1016\/j.jval.2020.09.004_bib88","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1016\/j.vaccine.2018.02.038","article-title":"Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010-2015","volume":"36","author":"Parikh","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jval.2020.09.004_bib52","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jval.2020.09.004_bib55","doi-asserted-by":"crossref","unstructured":"Weil-Olivier C, Taha MK, Emery C, et\u00a0al. Description of patients hospitalized with meningococcal infections in France: an analysis of the national healthcare claim(SNIIR-AM) database. Paper presented at ISPOR Europe 2019; Copenhagen, Denmark.","DOI":"10.1016\/j.jval.2019.09.1346"},{"issue":"7","key":"10.1016\/j.jval.2020.09.004_bib56","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1469-8749.2008.03000.x","article-title":"Life expectancy in cerebral palsy: an update","volume":"50","author":"Strauss","year":"2008","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.jval.2020.09.004_bib64","doi-asserted-by":"crossref","unstructured":"Sevilla J, Tortorice D, Kantor D, et\u00a0al. Lifecycle-model-based economic evaluation of infant meningitis B vaccination in the UK. Paper presented at: ISPOR2019; Copenhagen, Denmark.","DOI":"10.1016\/j.jval.2019.09.1286"},{"issue":"2","key":"10.1016\/j.jval.2020.09.004_bib65","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10198-019-01129-z","article-title":"Economic evaluation of meningococcal vaccines: considerations for the future","volume":"21","author":"Christensen","year":"2020","journal-title":"Eur J Health Econ"},{"issue":"4","key":"10.1016\/j.jval.2020.09.004_bib68","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40273-019-00789-2","article-title":"Measuring health spillover effects in caregivers of children with autism spectrum disorder: a comparison of the EQ-5D-3L and SF-6D","volume":"37","author":"Brown","year":"2019","journal-title":"PharmacoEconomics"},{"issue":"3","key":"10.1016\/j.jval.2020.09.004_bib71","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40273-015-0335-2","article-title":"Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community","volume":"34","author":"Ultsch","year":"2016","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jval.2020.09.004_bib75","author":"Hernandez-Villafuerte"},{"issue":"6","key":"10.1016\/j.jval.2020.09.004_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197374","article-title":"The views of the general public on prioritising vaccination programmes against childhood diseases: a qualitative study","volume":"13","author":"Lasseter","year":"2018","journal-title":"PloS One"},{"issue":"9895","key":"10.1016\/j.jval.2020.09.004_bib80","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(13)61862-0","article-title":"Correspondence: Immunisation against meningococcus B","volume":"382","author":"Plotkin","year":"2013","journal-title":"Lancet"},{"issue":"9895","key":"10.1016\/j.jval.2020.09.004_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)61863-2","article-title":"Correspondence: Immunisation against meningococcus B","volume":"382","author":"Black","year":"2013","journal-title":"The Lancet"},{"issue":"9","key":"10.1016\/j.jval.2020.09.004_bib82","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40273-016-0414-z","article-title":"Extended cost-effectiveness analysis for health policy assessment: a tutorial","volume":"34","author":"Verguet","year":"2016","journal-title":"PharmacoEconomics"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520344041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520344041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:22:48Z","timestamp":1761096168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520344041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1098301520344041"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.09.004","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}